Financials & Filings

OTCQB: INTI
PRICE:
Stock Info

This section of the Inhibitor Therapeutics InvestorRoom houses up to date financial reporting information and interactive tools to provide you with the resources you need to manipulate and understand our current financial standing. 

Please note:  All data in this section is provided by a 3rd party provider and may be delayed up to 20 minutes.  Inhibitor Therapeutics assumes no responsibility for the accuracy of this data and provides it for informational purposes only.

Beta(0.81)
Shares Outstanding172.3M
Average Volume (10 days)11.8K
Qtrly Dividend (Ann. Yield)-- (--)

Per Share Data

Earnings (TTM)--
Sales (TTM)--
Book Value (MRQ)$0.04
Cash Flow (TTM)$0.06
Cash (MRQ)$0.06

Analyst Views

Current Mean RecommendationN/A
Strong Buy0
 
Buy0
 
Hold0
 
Underperform0
 
Sell0
 

Recent Insider Transactions

Santelli Jonathan
25,000
Acquire
Aug 11, 2023
Debra Peattie
Director
580,646
Acquire
Dec 22, 2020
Virca Nicholas
Ceo/President
125,000
Acquire
Dec 22, 2020
Robert Martin
Director
754,839
Acquire
Dec 22, 2020
Watson W.
Director
1,306,452
Acquire
Dec 22, 2020

Recent SEC Filings

Insider Buy/Sell
May 16, 2024
Insider Buy/Sell
May 16, 2024
Insider Buy/Sell
May 16, 2024
Insider Buy/Sell
May 16, 2024
Insider Buy/Sell
May 16, 2024
Get Important News and Updates by Email
* Required Fields